103 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
to the Occupational Health and Safety Act) relating to the protection of human health and safety in the workplace (“Occupational Laws”); (ii) has received all … , market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other notice of action relating to an alleged
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
and sought continued treatment with DCCR were eligible to receive DCCR in a long-term open-label safety extension Study (C602). Top line results from DESTINY … and IV formulations have been withdrawn from the U.S. market for reasons other than safety. There is extensive data on short term and chronic use
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
treatment with DCCR were eligible to receive DCCR in a long-term open-label safety extension Study (C602). Top line results from DESTINY PWS were … formulations have been withdrawn from the U.S. market for reasons other than safety. There is extensive data on short term and chronic use of Proglycem
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
to be generally well-tolerated in the randomized withdrawal period with no new or unexpected safety signals.
Planned submission of a New Drug
S-3ASR
nrw3d46sfdlj8 cdl
2 Jan 24
Automatic shelf registration
4:06pm
8-K
EX-10.1
a3z tb550
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
79e pgquooyy489
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
5pzygkk
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
9bdqwvtum
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
j0dvu3z vmf991n
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
lpbn0hrgd1
10 Jul 23
Regulation FD Disclosure
4:06pm